Argenx combines strong early commercial success with a powerful scientific platform and a conservative balance sheet. It enjoys very high margins, solid profitability, and strong cash generation for a biotech at its stage, all supported by substantial cash reserves and minimal debt. Scientifically, it leads in FcRn‑based therapies and possesses differentiated antibody engineering capabilities, a deep network of academic partners, and a clear strategic roadmap through its Vision 2030 plan.

Key risks center on concentration, competition, and execution. The business is heavily reliant on VYVGART and the FcRn mechanism, making it sensitive to competitive data, pricing dynamics, and any regulatory or safety issues. Large pharmaceutical players are entering the same space, which may pressure market share and margins. Historical losses, negative retained earnings, and reliance on equity funding highlight the inherently risky and capital‑intensive nature of its model, while ongoing R&D and working capital swings can add earnings and cash flow volatility.

The overall picture is of a high‑potential, innovation‑driven biotech that has successfully crossed into profitability but still faces the usual sector uncertainties. If Argenx can defend and expand VYVGART, bring additional indications to market, and advance its next wave of pipeline assets, it has room to grow into a more diversified autoimmune franchise. At the same time, investors should expect a bumpy path with meaningful scientific, competitive, and regulatory risk typical of advanced-stage biotechnology companies.